For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
InspireMD is Also Proud to Announce That MGuard(TM) is Now Available With an Improved Delivery System. Final 6 Month Results of the MAGICAL Trial and Final 1 Year Results of the INSPIRE Study Will be Presented During EuroPCR 2010
PARIS, May 26, 2010 /PRNewswire/ -- InspireMD, Ltd. announced today the next generation MGuard stent, MGuard Prime(R), a net protective Cobalt Chromium stent system. MGuard Prime(R) offers an advanced patented Cobalt Chromium design, superior flexibility and excellent deliverability on top of the established benefits of the MGuard MicroNet(R) technology.
MGuard(TM) is now available with an improved delivery system. Recently InspireMD introduced MGuard with a new improved delivery system in selected regions. The new delivery system offers a state of the art design and a superior deliverability. "We are very pleased with the flexibility and performance of the new delivery system. In our testing we have experienced a 15% improvement in crossing profile and 45% improvement in pushability resistance. These improvements will directly benefit Acute MI patients throughout the world," said Eli Bar, CTO and VP R&D of InspireMD.
InspireMD will hold an Evening Symposium at the PCR this evening at 6:30-8:00pm at the Concorde Lafayette Hotel in Paris. The symposium "MGuard - 2 Years Experience in Acute MI" will be chaired by Dr. Martin B. Leon.
MGuard final adjudicated results of the MAGICAL trial, including the long awaited 6 months clinical FU results, will be presented for the first time at the EuroPCR. The MAGICAL Trial is a 60 patients STEMI study. Acute results as well as interim 30 day clinical results have previously been presented by Dr. Dariusz Dukek, the study's primary investigator.
Also coming up at the EuroPCR, presented for the first time, the final adjudicated results of the INSPIRE trial, and long awaited 1 year clinical FU with 6 month angiographic results.
The INSPIRE Trial from Sao-Paulo, Brazil is a 30 patients' study that enrolled SVG and native coronary patients. Acute results as well as interim results have previously been presented by Dr. A. Abizaid, the study's primary investigator.
The international iMOS registry has crossed the 200 patients' milestone. The registry will enroll 1000 'real world' MGuard(TM) patients in Europe, Asia and South America. Data from the registry, an unselected heterogeneous population, will be used to support data from other clinical studies. Interim data analysis will be presented by Prof. GB. Danzi, from the iMOS steering committee, at InspireMD's evening symposium this evening.
About MGuard(TM) Coronary
MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The protective sleeve is composed of a micron-level-fiber which is knit in order to ensure flexibility while retaining the strength characteristics of the fiber material. The sleeve is designed to expand seamlessly when the stent is deployed, without affecting the structural integrity of the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without complicating deliverability. Reduced injury to the vessel as a result of diffused stent pressure is a benefit of the sleeve which may lead to lower risk of restenosis. MGuard(TM) is CE Mark approved.
The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.
InspireMD Ltd. is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis. In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.
For further information visit http://www.inspire-md.com Contact: Jonina Ohayon Marketing Director Tel +972-52-5791120 email@example.com
More by this Source
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
Nov 11, 2013, 16:01 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.